(Q35574952)

8 August 2017

1 reference

title

Pharmacogenetic candidate genes for melanoma (English)

1 reference

8 August 2017

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

author name string

Christopher Hull

1

1 reference

8 August 2017

April Larson

2

1 reference

8 August 2017

Sancy Leachman

3

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14596639

28 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

https://www.futuremedicine.com/doi/pdf/10.1517/phgs.4.6.753.22819

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

1 reference

8 August 2017

4

1 reference

8 August 2017

6

1 reference

8 August 2017

753-765

1 reference

Melanoma etiology: where are we?

8 August 2017

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

21 January 2018

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Biochemotherapy for advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Classical chemotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Pharmacogenetics in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Pharmacogenetics and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

The genetics of malignant melanoma: lessons from mouse and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Geographical variation in the penetrance of CDKN2A mutations for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Genetics of melanoma predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

The pathogenesis of melanoma induced by ultraviolet radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Translational oncogenomics: toward rational therapeutic decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Gene-expression profiling in human cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Study of the development of chemoresistance in melanoma cell lines using proteome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Germline p16 mutations in familial melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Mortality from second tumors among long-term survivors of retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Pathways to melanoma development: lessons from the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Human melanocyte senescence and melanoma susceptibility genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Melanoma cell autonomous growth: the Rb/E2F pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Small molecule modulators of cyclin-dependent kinases for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

TP53 mutations in human skin cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

A melanoma-associated germline mutation in exon 1beta inactivates p14ARF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

The regulation of normal melanocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Regulation of the human melanocortin 1 receptor expression in epidermal melanocytes by paracrine and endocrine factors and by ultraviolet radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Mitogen- and ultraviolet-B-induced signaling pathways in normal human melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

21 January 2018

Oncogenes in melanoma

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Malignant melanoma: modern black plague and genetic black box.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

The protein Id: a negative regulator of helix-loop-helix DNA binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Coupling of cell growth control and apoptosis functions of Id proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Id helix-loop-helix proteins in cell growth and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

A novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Skin colour and skin cancer - MC1R, the genetic link

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Genetic association and cellular function of MC1R variant alleles in human pigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Evidence for variable selective pressures at MC1R

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Melanocortin 1 receptor variants in an Irish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

PTEN signaling pathways in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Prognostic significance of allelic losses in primary melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Role and regulation of the thrombin receptor (PAR-1) in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Update on pharmacogenetics in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Retinoblastoma, melanoma and the atypical mole syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

An analysis of p16 protein expression in sporadic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Germline mutation of ARF in a melanoma kindred

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Loss of p16 expression is associated with histological features of melanoma invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

CDKN2A germline splicing mutation affecting both p16ink4 and p14arf RNA processing in a melanoma/neurofibroma kindred

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Loss of p14ARF expression in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.6.753.22819

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

Biochimica et Biophysica Acta

28 March 2024

12

17

99

Watters JW

2003

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

Molecular portraits and the family tree of cancer

28 March 2024

21

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus

28 March 2024

29

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

Biochimica et Biophysica Acta

28 March 2024

37

1378

F115

Ruas M

1998

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

60

55

4278

Levin DB

1995

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

67

61

7642

Polsky D

2001

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

79

49

4682

Bos

1989

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

97

59

1726

Israel MA

1999

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

116

63

2881

Stahl JM

2003

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

121

57

5221

Teng DH

1997

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

124

60

1800

Tsao H

2000

1 reference

https://api.crossref.org/works/10.1517/PHGS.4.6.753.22819

28 March 2024

Identifiers

1 reference

8 August 2017

1 reference